Elutia Inc. (ELUT) AI Stock Analysis

Elutia Inc., formerly known as Aziyo Biologics, Inc., develops drug-eluting biomatrix products used in surgical reconstruction and related applications. It operates through two segments: Women's Health and Cardiovascular. Its lead development programs, NXT-41 and NXT-41x, combine biologic scaffolds with local antibiotic delivery. The company's commercial portfolio includes SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction, alongside cardiac solutions such as ProxiCor, Tyke, and VasCure. Products are distributed directly to hospitals and healthcare facilities via independent sales agents.

Elutia's revenue contracted at a five-year CAGR of -22.0% from FY2020 to FY2025. In FY2025, revenue decreased 49.6% to $12.3M from $24.4M in FY2024, while gross margin improved to 53.7% from 43.9%. Operating margin remained negative at -149.8% in FY2025, although net income reached $53.4M, resulting in diluted EPS of $0.95. For the trailing twelve months ended June 30, 2026, revenue stood at $12.1M with an operating margin of -243.1% and diluted EPS of -$0.64. In the latest quarter ended June 30, 2026, revenue declined 11.6% year-over-year.

As of June 30, 2026, Elutia held $19.9M in cash and short-term investments and $10.8M in total debt, yielding net cash of $9.1M. Shareholders' equity was $15.7M, supporting a debt-to-equity ratio of 0.69 and a current ratio of 1.77. In FY2025, operating cash flow was -$44.8M and capital expenditures were $1.9M, leading to free cash flow of -$46.7M. The company's share count increased 293.6% over the past five years.

Elutia trades at a price-to-sales multiple of 2.9x and an enterprise value to revenue multiple of 1.9x, compared to the median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio stands at 2.4x with a market capitalization of $35.2M. Over the past year, ELUT shares decreased 11.8%, while the S&P 500 (SPY) gained 16.8%. Over a five-year period, ELUT dropped 85.4% versus an 83.0% gain for the benchmark.

One analyst covers Elutia with a Strong Buy rating. The mean price target of $5.00 represents a 529.7% premium over the last close of $0.79. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $7.5M and EPS of -$0.63. For FY2027, the revenue estimate is $4.3M, representing a 42.7% decline, with EPS projected at -$0.54. The company beat EPS estimates in two of the last four quarters. Its next earnings report is scheduled for November 5, 2026.

This page is an AI-written research summary of Elutia Inc. (ELUT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELUT income statement, ELUT balance sheet, ELUT key metrics, ELUT analyst forecast, ELUT chart. See the ELUT stock overview for the latest quote and news.